



Synthesis and Antimicrobial Activity of 1-Substituted Phenyl-3-substituted Phenyl-4-[(3,4,5-trimethoxy)-5-benzyl]-4-aminopyrimidine Formazans

A. NARENDRA BABU* and RAMA RAO NADENDLA

Chalpathi Institute of Pharmaceutical Sciences, Guntur-522 034, India

*Corresponding author: E-mail: narendraankem@rediffmail.com

(Received: 23 February 2010;

Accepted: 27 August 2010)

AJC-9037

A series of 15 novel 1-substituted phenyl-3-substituted phenyl-4-[(3,4,5-trimethoxy)-5-benzyl]-4-amino pyrimidine formazans [2a-2o] were synthesized from trimethoprim. All the compounds were characterized by analytical and spectral analysis. The antibacterial and antifungal activities were screened for all the compounds. The synthesized compounds were found to have significant effect against the tested organisms.

Key Words: Synthesis, Pyrimidine formazans, Antibacterial, Antifungal.

INTRODUCTION


Pyrimidine nucleus has wide range of importance in medicinal chemistry, due to wide spectrum of biological activities exhibited by them. Pyrimidines and formazans have exhibited a variety of biological activities. Literature survey revealed that various substituted pyrimidines are known to possess antimicrobial^{1,2}, antiinflammatory³, herbicidal⁴, anticancer⁵, antiviral⁶, antimalarial⁷ and other miscellaneous activities while formazans show promising antifertility⁸, antiparkinsonian⁹, anticancer¹⁰, antibacterial¹¹⁻¹³, antifungal¹¹⁻¹³, antiviral¹⁴, antidepressant¹⁵, MAO inhibitory¹⁵, antiinflammatory¹⁶ activities.

All these valid observations led us to synthesize some new pyrimidine formazan derivatives to explore their possible biological activities.

EXPERIMENTAL

Melting points of the newly synthesized compounds were determined by open capillary method and uncorrected. Purity of the compound was checked by TLC using silica gel-G plate, chloroform:benzene (8.5:1.5) as mobile phase and iodine vapours as detecting agent. IR spectra (KBr , ν_{max} , cm^{-1}) were recorded on Perkin Elmer FTIR spectrophotometer. ^1H NMR spectra were recorded on Bruker AMX 400 MHz instrument using TMS as internal standard. Mass spectra were recorded on Agilent LC-MSD spectrometer.

The synthesis of 1-substituted phenyl-3-substituted phenyl-4-[(3,4,5-trimethoxy)-5-benzyl]-4-amino pyrimidine formazans is given in the **Scheme-I**. The physical data are given in Table-1.



Synthesis of N-substituted phenyl-4-[(3,4,5-trimethoxy)-5-benzyl]-4-aminopyrimidine azomethines (1): A mixture of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine

TABLE-1
 PHYSICAL DATA OF SYNTHESIZED COMPOUNDS

Compound	Ar ₁	Ar ₂	Physical state	m.f. (m.w.)	m.p. (°C)	Yield (%)
2a	C ₆ H ₅	C ₆ H ₄ Cl	Yellow amorphous	C ₂₇ H ₂₅ N ₆ O ₃ Cl (517)	144	63.3
2b	C ₆ H ₅	C ₆ H ₄ Br	Brown amorphous	C ₂₇ H ₂₅ N ₆ O ₃ Br (561.4)	218	58.5
2c	C ₆ H ₅	C ₆ H ₄ NO ₂	Brown amorphous	C ₂₇ H ₂₃ N ₇ O ₅ (527.5)	280	61.2
2d	C ₆ H ₅	C ₆ H ₃ FCl	Black amorphous	C ₂₇ H ₂₄ N ₆ O ₃ FCl (535)	198	58.0
2e	C ₆ H ₄ Cl	C ₆ H ₄ Cl	Pale yellow amorphous	C ₂₇ H ₂₄ N ₆ O ₃ Cl ₂ (551.4)	138	67.2
2f	C ₆ H ₄ Cl	C ₆ H ₄ Br	Pale yellow amorphous	C ₂₇ H ₂₄ N ₆ O ₃ ClBr (596)	226	66.3
2g	C ₆ H ₄ Cl	C ₆ H ₄ NO ₂	Pale brown amorphous	C ₂₇ H ₂₄ N ₇ O ₅ Cl (562)	292	65.1
2h	C ₆ H ₄ Cl	C ₆ H ₃ FCl	Pale brown amorphous	C ₂₇ H ₂₃ N ₆ O ₃ FCl (534)	214	70.0
2i	C ₆ H ₄ NO ₂	C ₆ H ₄ Br	Yellow amorphous	C ₂₇ H ₂₄ N ₇ O ₅ Br (606.4)	162	62.3
2j	C ₆ H ₄ NO ₂	C ₆ H ₄ NO ₂	Brown amorphous	C ₂₇ H ₂₄ N ₈ O ₇ (572.5)	258	58.9
2k	C ₆ H ₄ NO ₂	C ₆ H ₃ FCl	Black crystalline	C ₂₇ H ₂₃ N ₇ O ₅ FCl (580)	190	61.0
2l	C ₆ H ₄ N(CH ₃) ₂	C ₆ H ₄ Cl	Pale yellow amorphous	C ₂₉ H ₃₀ N ₇ O ₃ Cl (560)	186	59.3
2m	C ₆ H ₄ N(CH ₃) ₂	C ₆ H ₄ Br	Brown amorphous	C ₂₉ H ₃₀ N ₇ O ₃ Br (604.5)	260	60.4
2n	C ₆ H ₄ N(CH ₃) ₂	C ₆ H ₄ NO ₂	Brown amorphous	C ₂₉ H ₃₀ N ₈ O ₅ (570.6)	310	66.2
2o	C ₆ H ₄ N(CH ₃) ₂	C ₆ H ₃ FCl	Black crystalline	C ₂₉ H ₂₉ N ₇ O ₃ FCl (578)	272	56.9

(trimethoprim) (0.1 mol) and aldehyde or substituted aldehyde (0.1 mol) in alcohol were refluxed for 6 h and poured into ice-cold water. The resulting mass was washed with water for several times and crystallized from DMSO.

Synthesis of 1-substituted phenyl-3-substituted phenyl-4-[(3,4,5-trimethoxy)-5-benzyl]-4-amino pyrimidine formazans (2a-2o): The diazonium salts obtained from the respective amines (0.01 mol) were added with stirring to N-substituted phenyl-4-[(3,4,5-trimethoxy)-5-benzyl]-4-amino pyrimidine azomethines (0.01 mol) in pyridine at 0-5 °C for 0.5 h. The mixture was poured into cold water. The resulting product was filtered, dried and crystallized from DMSO.

2b: IR (KBr, ν_{\max} , cm⁻¹): 1596 (C=N), 1512 (N=N), 3438 (N-H), 1485 (aromatic C=C), 1196 (C-O, -OCH₃), 3193 (C-H, -CH₂), 825 (C-Cl). ¹H NMR (δ ppm): 7.443-7.528 (m, 12H, Ar-H), 3.322 (s, 2H, -NH₂), 3.322 (s, 3H, -OCH₃), 2.507-2.511 (s, 2H, -CH₂).

2c: IR (KBr, ν_{\max} , cm⁻¹): 1595 (C=N), 1515 (N=N), 3442 (N-H), 1167 (C-O, -OCH₃), 1342 (N-O, -NO₂), 3278 (C-H, -CH₂). ¹H NMR (δ ppm): 7.694-8.459 (m, 12H, Ar-H), 3.325 (s, 2H, -NH₂), 3.752 (s, 3H, -OCH₃), 2.512 (s, 2H, -CH₂). MS: m/z (M⁺) 529.

2e: IR (KBr, ν_{\max} , cm⁻¹): 1595 (C=N), 1507 (N=N), 3437 (N-H), 1462 (aromatic C=C), 1195 (C-O, -OCH₃), 3158 (C-H, -CH₂), 827 (C-Cl). ¹H NMR (δ ppm): 6.067-8.588 (m, 11H, Ar-H), 3.333 (s, 2H, -NH₂), 3.534-3.730 (s, 3H, -OCH₃), 2.511 (s, 2H, -CH₂).

2f: IR (KBr, ν_{\max} , cm⁻¹): 1593 (C=N), 1506 (N=N), (aromatic C=C), 1195 (C-O, -OCH₃), 3323 (N-H), 3157 (C-H, -CH₂), 824 (C-Cl), 706 (C-Br). ¹H NMR (δ ppm): 6.062-8.591 (m, 11H, Ar-H), 3.328 (s, 2H, -NH₂), 3.532-3.728 (s, 3H, -OCH₃), 2.506-2.514 (s, 2H, -CH₂).

2g: IR (KBr, ν_{\max} , cm⁻¹): 1594 (C=N), 1513 (N=N), 3472 (N-H, primary amine), 1165 (C-O, -OCH₃), 1340 (N-O, -NO₂), 1474.86 (aromatic C=C), 3281 (C-H, -CH₂), 857 (C-Cl). ¹H NMR (δ ppm): 7.373-8.588 (m, 11H, Ar-H), 3.326 (s, 2H, -NH₂), 3.535-3.730 (s, 3H, -OCH₃), 2.506-2.510 (s, 2H, -CH₂).

2i: IR (KBr, ν_{\max} , cm⁻¹): 1597 (C=N), 1511 (N=N), 3436 (N-H, primary amine), 1196 (C-O, -OCH₃), 1346 (N-O, -NO₂), 1482 (aromatic C=C), 3195 (C-H, -CH₂), 735.39 (C-Br). ¹H NMR (δ ppm): 7.567-8.439 (m, 11H, Ar-H), 3.321 (s, 2H,

-NH₂), 3.643-3.753 (s, 3H, -OCH₃), 2.505-2.514 (s, 2H, -CH₂). MS: m/z (M⁺) 602.7.

2j: IR (KBr, ν_{\max} , cm⁻¹): 1600 (C=N), 1520 (N=N), 3271 (N-H), 1194 (C-O, -OCH₃), 1344 (N-O, -NO₂), 3104 (C-H, -CH₂). ¹H NMR (δ ppm): 6.617-8.453 (m, 11H, Ar-H), 3.335 (s, 2H, -NH₂), 3.752 (s, 3H, -OCH₃), 2.510-2.512 (s, 2H, -CH₂). MS: m/z (M⁺) 575.1.

2k: IR (KBr, ν_{\max} , cm⁻¹): 1598 (C=N), 1498 (N=N), 3387 (N-H), 1196 (C-O, -OCH₃), 3103 (C-H, -CH₂), 1344 (N-O, -NO₂), 1196 (C-F), 815 (C-Cl). ¹H NMR (δ ppm): 6.577-8.427 (m, 11H, Ar-H), 3.337 (s, 2H, -NH₂), 3.757 (s, 3H, -OCH₃), 2.475-2.511 (s, 2H, -CH₂). MS: m/z (M⁺) 562.

2n: IR (KBr, ν_{\max} , cm⁻¹): 1594 (C=N), 1516 (N=N), 3369 (N-H), 1164 (C-O, -OCH₃), 1447 (aromatic C-C), 3071 (C-H, -CH₂), 1340 (N-O, -NO₂). ¹H NMR (δ ppm): 6.780-8.457 (m, 11H, Ar-H), 3.332 (s, 2H, -NH₂), 3.701-3.751 (s, 3H, -OCH₃), 2.505-2.514 (s, 2H, -CH₂), 1.932 (s, 3H, -CH₃).

2o: IR (KBr, ν_{\max} , cm⁻¹): 1599.82 (C=N), 1524.84 (N=N), 3388 (N-H), 1195 (C-O, -OCH₃), 1499 (aromatic C=C), 3103 (C-H, -CH₂), 1122 (C-F, aryl fluoride), 815 (C-Cl). ¹H NMR (δ ppm): 6.604-8.855 (s, 11H, Ar-H), 3.344 (s, 2H, -NH₂), 3.748 (s, 3H, -OCH₃), 2.511 (s, 2H, -CH₂), 1.918-1.920 (s, 3H, CH₃).

Antimicrobial screening: Antibacterial activity of synthesized compounds were screened against *Escherichia coli*, *Pseudomonas aeruginosa*, *Bacillus subtilis*, *Bacillus cereus*, *Staphylococcus aureus* and *Staphylococcus epidermidis* using paper disc diffusion method. The compounds were tested at 10 mg/mL level. The results were compared with ciprofloxacin (100 µg/disc). All the compound showed moderate to significant antibacterial activity (Table-2).

Antifungal activity of the synthesized compounds were screened against *Aspergillus niger*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida glabrata* using paper disc diffusion method at 10 mg/mL level. Fluconazole (100 µg/disc) was used as standard for comparison. All the compounds showed moderate to significant activity (Table-2).

RESULTS AND DISCUSSION

Various 1-substituted phenyl-3-substituted phenyl-4-[(3,4,5-trimethoxy)-5-benzyl]-4-amino pyrimidine formazan

TABLE-2
ANTIMICROBIAL SCREENING-ZONE OF INHIBITION (mm)

Microorganism (bacteria)	2a	2b	2c	2d	2e	2f	2g	2h	2i	2j	2k	2l	2m	2n	2o	Std.*
<i>E. coli</i>	19	18	20	17	17	15	16	20	19	21	20	9	5	15	12	22
<i>P. aeruginosa</i>	5	–	12	9	11	13	11	5	21	20	18	6	5	13	17	21
<i>B. subtilis</i>	25	24	22	25	15	16	13	–	25	25	15	–	5	24	14	21
<i>B. cereus</i>	–	8	13	8	13	13	15	8	19	17	15	–	6	14	13	17
<i>S. aureus</i>	–	9	15	10	12	18	20	22	22	21	21	20	15	13	18	20
<i>S. epidermidis</i>	25	19	25	24	17	17	16	24	24	26	14	–	11	14	18	20
Microorganism (fungi)																
<i>A. niger</i>	–	–	21	–	9	13	18	14	23	21	26	10	14	16	–	17
<i>S. cerevisiae</i>	–	8	23	8	11	12	14	–	16	22	19	10	13	22	–	18
<i>C. albicans</i>	–	6	18	10	15	7	10	14	20	20	17	9	10	12	8	19
<i>C. glabrata</i>	10	7	24	16	9	19	18	20	22	24	20	8	10	23	10	22

derivatives were synthesized from trimethoprim. The structures of the synthesized compounds were confirmed by IR, ¹H NMR and mass spectral analysis. The compounds having aryl nitro, fluorine and chlorine at 4th position of one phenyl ring along with formazan nucleus enhances biological activity. The compounds **2c**, **2i**, **2j**, **2k**, **2n** and **2o** have exhibited significant antibacterial activity where as compounds **2e**, **2f** and **2g** shown good antibacterial activity when compared with standard drug ciprofloxacin. The compounds **2c**, **2i**, **2j**, **2k** and **2n** exhibited significant antifungal activity when compared with the standard drug fluconazole.

ACKNOWLEDGEMENT

The authors are grateful to Chalapathi Institute of Pharmaceutical Sciences, Guntur for providing necessary facilities to carry out this research work.

REFERENCES

- N.M. Goudgaon and Ch.U. Reddy, *J. Indian Chem. Soc.*, **86**, 617 (2009).
- Abdel-Gawad, S.M. Ghorab, M.M. El-Sharief, El. Telbany and F.A. Abdel-Alla, *Heteroatom Chem.*, **14**, 530 (2003).
- S. Ihsan, *J. Saudi Chem. Soc.*, **14**, 43 (2003).
- K. Tanaka, A. Takahashi, N. Umeda, H. Yamada, H. Adachi and T. Kawana, *Pesticide Sci.*, **55**, 370 (1999).
- T.Y. Fahmy Hesham, A.F. Rostom Sherif, N.S. Manal, K.Z. Jordan and J.R. David, *Arch. Pharm.*, **336**, 216 (2003).
- A.F. Rostom Sherif, T.Y. Fahmy Hesham and N.S. Manal, *Saudi Sci. Pharm.*, **71**, 57 (2003).
- A. Anu, S. Kumkum, S.K. Puri and M.S. Chauhan Prem, *Bioorg. Med. Chem.*, **13**, 6226 (2005).
- J.M. Desai and V.H. Shah, *Indian J. Chem.*, **42B**, 631 (2003).
- R. Khanna, A.K. Saxena, V.K. Srivastava and K. Shanker, *Indian J. Chem.*, **29B**, 91 (1990).
- S.D. Bhardwaj, P. Phatak and V.S. Jolly, *Orient J. Chem.*, **2**, 181 (1995).
- B.H. Trivedi and V.H. Shah, *J. Indian Chem. Soc.*, **69**, 765 (1992).
- E. Stefanescu, M. Dorneanu, C. Danila, C. Aprotosoiaie, G. Grosu and M. Pavelescu, *Rev. Med. Chir. Soc. Med. Nat. Iasi.*, **101**, 178 (1997).
- K.G. Desai and K.R. Desai, *Indian. J. Chem.*, **44(B)**, 2097 (2005).
- V.S. Misra, S. Dhar and B.L. Chowdary, *Pharmazie*, **33**, 790 (1978).
- G. Sathi, V.R. Gujrati, C. Nath, J.C. Agarwal, K.P. Bhargava and K. Shanker, *Arzneimittelforschung*, **33**, 1218 (1983).
- R. Kalsi, K. Pande, T.N. Bhalla, S.S. Parmar and J.P. Barthwal, *J. Pharmacol.*, **37**, 218 (1988).